Alphatec Holdings, Inc. (NASDAQ:ATEC) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC) have been given a consensus rating of “Moderate Buy” by the nine brokerages that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $17.11.

ATEC has been the topic of several research analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $13.00 price target on shares of Alphatec in a research report on Thursday, October 31st. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Alphatec in a report on Thursday, October 31st. Barclays raised their target price on shares of Alphatec from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Tuesday, November 19th. Finally, Lake Street Capital lowered their target price on Alphatec from $32.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd.

Institutional Investors Weigh In On Alphatec

A number of hedge funds have recently made changes to their positions in ATEC. Franklin Resources Inc. grew its stake in shares of Alphatec by 299.3% in the third quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company’s stock worth $343,000 after purchasing an additional 48,308 shares in the last quarter. Barclays PLC boosted its stake in Alphatec by 362.3% during the third quarter. Barclays PLC now owns 170,546 shares of the medical technology company’s stock valued at $948,000 after buying an additional 133,653 shares in the last quarter. Invst LLC boosted its stake in Alphatec by 3.7% during the third quarter. Invst LLC now owns 158,549 shares of the medical technology company’s stock valued at $882,000 after buying an additional 5,630 shares in the last quarter. Y Intercept Hong Kong Ltd acquired a new position in Alphatec during the third quarter worth about $147,000. Finally, XTX Topco Ltd bought a new stake in Alphatec in the third quarter worth about $69,000. Institutional investors own 66.35% of the company’s stock.

Alphatec Trading Down 1.5 %

NASDAQ ATEC opened at $9.19 on Friday. The company has a market capitalization of $1.30 billion, a price-to-earnings ratio of -7.18 and a beta of 1.38. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. Alphatec has a 12 month low of $4.88 and a 12 month high of $17.34. The company’s fifty day moving average price is $8.74 and its two-hundred day moving average price is $8.10.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.